See more : Aspocomp Group Oyj (ACG1V.HE) Income Statement Analysis – Financial Results
Complete financial analysis of StageZero Life Sciences Ltd. (SZLSF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of StageZero Life Sciences Ltd., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Scout24 SE (G24.DE) Income Statement Analysis – Financial Results
- Barrick Gold Corporation (GOLD) Income Statement Analysis – Financial Results
- KIMIA BIOSCIENCES LIMITED (KIMIABL.BO) Income Statement Analysis – Financial Results
- Aino Health AB (publ) (AINO.ST) Income Statement Analysis – Financial Results
- Societal CDMO, Inc. (SCTL) Income Statement Analysis – Financial Results
StageZero Life Sciences Ltd. (SZLSF)
Industry: Medical - Diagnostics & Research
Sector: Healthcare
About StageZero Life Sciences Ltd.
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in the United States and Canada. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is Aristotle, a multi-cancer panel test for simultaneously screening for various cancers from a single sample of blood with high sensitivity and specificity for each cancer. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; COVID polymerase chain reaction testing and blood test analysis; Prostate Health Index, a screening test for prostate cancer; and BreastSentry, a test to determine a woman's risk for developing breast cancer. The company was founded in 1998 and is headquartered in Richmond Hill, Canada.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.80M | 5.07M | 4.15M | 138.70K | 185.87K | 411.67K | 1.05M | 325.81K | 2.11M | 124.08K | 281.56K | 98.73K | 193.48K | 1.09M | 1.17M | 2.19M | 2.82M | 4.60M | 1.85M | 2.91M | 151.65K | 0.65 | 0.67 | 67.91K | 0.65 |
| Cost of Revenue | 4.20M | 3.89M | 3.46M | 1.10M | 1.27M | 1.40M | 1.47M | 0.00 | 0.00 | 1.57M | 1.94M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -141.80K | -141.80K | 0.00 | 0.00 |
| Gross Profit | -403.75K | 1.18M | 695.56K | -960.91K | -1.08M | -992.71K | -414.70K | 325.81K | 2.11M | -1.45M | -1.65M | 98.73K | 193.48K | 1.09M | 1.17M | 2.19M | 2.82M | 4.60M | 1.85M | 2.91M | 151.65K | 141.80K | 141.80K | 67.91K | 0.65 |
| Gross Profit Ratio | -10.64% | 23.23% | 16.75% | -692.78% | -580.67% | -241.14% | -39.34% | 100.00% | 100.00% | -1,169.11% | -587.77% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 21,802,500.00% | 21,247,000.00% | 100.00% | 100.00% |
| Research & Development | 351.99K | 774.54K | 218.70K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.57M | 682.11K | 517.45K | 1.40M | 2.23M | 8.37M | 8.99M | 8.17M | 5.07M | 4.57M | 2.58M | 754.27K | 873.73K | 155.14K | 155.14K | 0.00 |
| General & Administrative | 5.91M | 6.98M | 4.02M | 4.18M | 3.29M | 4.17M | 3.85M | 2.77M | 3.38M | 2.36M | 3.17M | 2.76M | 2.10M | 2.66M | 3.19M | 3.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 746.41K | 1.24M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 401.75K | 822.96K | 1.14M | 363.36K | 38.40K | 168.98K | 436.49K | 383.54K | 0.83 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.65M | 8.22M | 4.02M | 4.18M | 3.29M | 4.17M | 3.85M | 3.18M | 4.21M | 3.50M | 3.53M | 2.80M | 2.27M | 3.09M | 3.58M | 3.16M | 2.25M | 1.92M | 1.64M | 664.79K | 278.95K | 386.37K | 91.59K | 27.96K | 6.80K |
| Other Expenses | 338.88K | 311.34K | 29.67K | 27.29K | 12.33K | 1.46M | 107.70K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 219.14K | -115.27K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 7.34M | 9.31M | 4.05M | 4.18M | 3.29M | 4.17M | 3.85M | 3.18M | 4.21M | 5.25M | 4.66M | 3.84M | 4.44M | 6.00M | 12.28M | 12.60M | 10.79M | 7.37M | 6.58M | 3.24M | 1.03M | 1.40M | 246.73K | 27.96K | 6.80K |
| Cost & Expenses | 11.54M | 13.20M | 7.51M | 5.28M | 4.55M | 5.57M | 5.32M | 3.18M | 4.21M | 5.25M | 4.66M | 3.84M | 4.44M | 6.00M | 12.28M | 12.60M | 10.79M | 7.37M | 6.58M | 3.24M | 1.03M | 1.26M | 246.73K | 27.96K | 6.80K |
| Interest Income | 0.00 | 0.00 | 35.09K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.66K | 45.65K | 12.90K | 23.37K | 9.30K | 15.17K | 170.56K | 830.34K | 384.52K | 152.09K | 63.47K | 71.56K | 13.42K | 127.68K | 127.68K | 0.00 | 623.05 |
| Interest Expense | 284.07K | 200.31K | 320.42K | 803.20K | 1.13M | 225.70K | 472.59K | 44.60K | 5.20K | 1.23M | 714.12K | 671.76K | 586.89K | 454.09K | 99.05K | 31.80K | 16.95K | 30.41K | 13.09K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 420.11K | 308.35K | 268.48K | 305.02K | 294.96K | 359.88K | 337.64K | 4.27K | 15.54K | 275.62K | 444.70K | 521.24K | 780.29K | 675.23K | 999.10K | 956.18K | 713.61K | 658.58K | 629.16K | 289.18K | 108.74K | 141.80K | 141.80K | 0.00 | 0.00 |
| EBITDA | -10.27M | -7.62M | -6.26M | -2.44M | -2.66M | -2.25M | -4.66M | -5.99M | -6.93M | -5.50M | -3.92M | -3.20M | -3.29M | -4.21M | -9.59M | -9.46M | -7.26M | -2.11M | -4.09M | -46.73K | -772.84K | -1.12M | -1.12M | -246.73K | -6.80K |
| EBITDA Ratio | -270.62% | -150.38% | -83.88% | -3,471.32% | -2,175.81% | -862.15% | -441.64% | -873.62% | -97.97% | -4,429.44% | -1,392.50% | -3,237.01% | -1,788.74% | -384.89% | -865.70% | -431.97% | -257.78% | -45.92% | -221.01% | -1.61% | -509.63% | -171,940,311.53% | -36,968,789.34% | 58.83% | -1,044,799.47% |
| Operating Income | -7.75M | -8.13M | -3.70M | -5.11M | -4.36M | -3.90M | -4.26M | -6.04M | -6.61M | -7.12M | -4.38M | -3.72M | -4.25M | -4.90M | -11.11M | -10.41M | -7.97M | -2.77M | -4.72M | -335.91K | -881.57K | -1.26M | -246.73K | 39.95K | -6.80K |
| Operating Income Ratio | -204.13% | -160.43% | -89.09% | -3,686.23% | -2,343.03% | -946.53% | -404.56% | -1,855.13% | -313.00% | -5,737.72% | -1,555.03% | -3,764.94% | -2,196.84% | -447.98% | -951.21% | -475.65% | -283.11% | -60.25% | -254.97% | -11.56% | -581.33% | -193,742,712.99% | -36,968,789.34% | 58.83% | -1,044,799.47% |
| Total Other Income/Expenses | -3.67M | 479.23K | -3.16M | 1.41M | 662.39K | 2.21M | -1.65M | -3.24M | -4.75M | -2.00M | -696.78K | -648.38K | -383.66K | -439.95K | 259.05K | 650.25K | 224.70K | 136.98K | 34.82K | 0.00 | 0.00 | 452.45K | 0.00 | 99.40K | 6.80K |
| Income Before Tax | -11.42M | -7.48M | -6.86M | -3.48M | -3.94M | -2.95M | -5.91M | -6.09M | -6.61M | -8.83M | -5.08M | -4.39M | -4.81M | -5.34M | -10.89M | -10.53M | -8.03M | 0.00 | 0.00 | 0.00 | 0.00 | -807.65K | 0.00 | -147.33K | 0.00 |
| Income Before Tax Ratio | -300.79% | -147.67% | -165.32% | -2,510.24% | -2,121.82% | -715.96% | -560.76% | -1,868.82% | -312.89% | -7,119.98% | -1,804.08% | -4,445.32% | -2,488.45% | -488.19% | -932.46% | -480.91% | -285.21% | 0.00% | 0.00% | 0.00% | 0.00% | -124,177,154.67% | 0.00% | -216.96% | 0.00% |
| Income Tax Expense | 0.00 | 200.31K | 320.42K | 830.49K | 1.14M | 1.69M | -88.66K | -71.98K | 5.20K | 540.60K | 12.90K | 0.00 | 586.89K | 454.09K | -71.51K | -798.54K | -367.57K | -121.68K | -50.38K | -71.56K | -13.42K | -127.68K | 246.73K | -2.82K | 6.18K |
| Net Income | -11.42M | -7.68M | -7.18M | -4.31M | -3.94M | -2.95M | -5.91M | -6.02M | -6.61M | -8.83M | -5.08M | -4.39M | -4.81M | -5.34M | -10.82M | -9.73M | -7.67M | -2.65M | -4.67M | -264.35K | -868.15K | -1.13M | -246.73K | -144.51K | -6.18K |
| Net Income Ratio | -300.79% | -151.62% | -173.04% | -3,108.99% | -2,121.82% | -715.96% | -560.76% | -1,846.73% | -312.89% | -7,119.98% | -1,804.08% | -4,445.32% | -2,488.45% | -488.19% | -926.34% | -444.43% | -272.16% | -57.60% | -252.25% | -9.10% | -572.48% | -174,111,211.67% | -36,968,889.34% | -212.80% | -949,199.51% |
| EPS | -0.11 | -0.11 | -0.16 | -0.16 | -0.23 | -0.24 | -0.72 | -0.90 | -1.12 | -2.07 | -2.23 | -2.34 | -3.11 | -4.02 | -8.74 | -7.89 | -7.03 | -3.02 | -5.94 | -0.44 | -1.75 | -3.32 | -1.28 | -3.61 | -0.15 |
| EPS Diluted | -0.11 | -0.11 | -0.16 | -0.16 | -0.23 | -0.24 | -0.72 | -0.90 | -1.12 | -2.07 | -2.23 | -2.34 | -3.11 | -4.02 | -8.74 | -7.89 | -7.03 | -3.02 | -5.94 | -0.44 | -1.75 | -3.32 | -1.28 | -3.61 | -0.15 |
| Weighted Avg Shares Out | 99.43M | 70.72M | 44.82M | 26.50M | 17.11M | 12.08M | 8.22M | 6.68M | 5.92M | 4.26M | 2.28M | 1.88M | 1.55M | 1.33M | 1.24M | 1.23M | 1.09M | 875.95K | 787.04K | 605.66K | 496.99K | 341.47K | 192.75K | 40.00K | 40.00K |
| Weighted Avg Shares Out (Dil) | 99.43M | 70.72M | 44.82M | 26.50M | 17.11M | 12.08M | 8.22M | 6.68M | 5.92M | 4.26M | 2.28M | 1.88M | 1.55M | 1.33M | 1.24M | 1.23M | 1.09M | 875.95K | 787.04K | 605.66K | 496.99K | 341.47K | 192.75K | 40.00K | 40.00K |
StageZero Life Sciences, Ltd. Special and Annual General Meeting Conference Call
Toronto, Ontario--(Newsfile Corp. - June 5, 2023) - StageZero Life Sciences, Ltd. (TSX: SZLS) ("StageZero" or the "Company") today announced that it will host a conference call as part of its Special and Annual General Meeting of Shareholders on Wednesday...
StageZero to Issue Q4 2022 Financial Results and Hold Conference Call on Thursday March 30
Toronto, Ontario--(Newsfile Corp. - March 29, 2023) - StageZero Life Sciences (TSX: SZLS) ("StageZero" or the "Company") today announced that it will release its fourth quarter and year end 2022 operational results after the market closes on Thursday March 30,...
StageZero Life Sciences Ltd. (SZLSF) Q3 2022 Earnings Call Transcript
StageZero Life Sciences Ltd. (OTCQB:SZLSF) Q3 2022 Earnings Conference Call November 15, 2022 8:30 AM ET Company Participants Rebecca Greco - Head, Investor Relations James R.
StageZero Life Sciences Ltd. (SZLSF) CEO James Howard-Tripp on Q2 2022 Results - Earnings Call Transcript
StageZero Life Sciences Ltd. (OTCQB:SZLSF) Q2 2022 Earnings Conference Call August 16, 2022 8:30 AM ET Company Participants Rebecca Greco - Head, Investor Relations James Howard-Tripp - Chairman & Chief Executive Officer Conference Call Participants Dipesh Patel - H.C.
StageZero Life Sciences Announces Results on Resolutions at Annual and Special Meeting
TORONTO, ON / ACCESSWIRE / June 28, 2022 / StageZero Life Sciences, Ltd (TSX:SZLS)(OTCQB:SZLSF) ("StageZero" or the "Company") is pleased to report that shareholders voted in favour of all of the tabled resolutions listed in the Company's management information circular...
StageZero Life Sciences Ltd. (SZLSF) CEO James Howard-Tripp on Q1 2022 Results - Earnings Call Transcript
StageZero Life Sciences Ltd. (OTCPK:SZLSF) Q1 2022 Earnings Conference Call May 17, 2022 8:30 AM ET Company Participants Rebecca Greco - Head of Investor Relations James Howard-Tripp - Chairman and Chief Executive Officer Matthew Pietras - Chief Financial Officer and...
StageZero to Issue Q3 2021 Financial Results and Hold Conference Call on Tuesday, November 16
TORONTO, ON / ACCESSWIRE / November 9, 2021 / StageZero Life Sciences (TSX:SZLS) (OTCQB:SZLSF) ("StageZero" or the "Company"), a healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through lab developed tests and...
StageZero Life Sciences Establishes On-Site Clinic for its Next-Generation Multi-Cancer Blood Test Aristotle(TM) in Richmond, Virginia
Patients in Virginia and the greater Washington, D.C. metropolitan area now have direct access to cancer testing at its Richmond lab TORONTO, ON and RICHMOND, VA / ACCESSWIRE / October 7, 2021 / StageZero Life Sciences, Ltd.
StageZero Life Sciences Announces Commencement of Trading on the OTCQB
TORONTO, ON / ACCESSWIRE / September 27, 2021 / StageZero Life Sciences, Ltd. (TSX:SZLS)(OTCQB:SZLSF) (the "Company" or "StageZero"), a healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through lab developed tests and...
StageZero Life Sciences Completes Acquisition of the Health Clinics Business
Transformational Acquisition Creates Vertically-integrated Healthcare Company with Next-Generation Diagnostic Capabilities and Advanced Telemedicine Platform TORONTO, ON / ACCESSWIRE / September 2, 2021 / StageZero Life Sciences, Ltd (TSX:SZLS)(OTC PINK:SZLSF) ("StageZero" or the "Company"), a healthcare company working to reduce the...
Source: https://incomestatements.info
Category: Stock Reports